New treasures from old ?<Tau Beta > EPHESUS

Impressive clinical benefits have been derived by inhibiting the renin-angi otensin-aldosterone system with angiotensin-converting enzyme inhibitors. T here is growing evidence that aldosterone plays a contributing role in the pathogenesis of heart failure beyond its sodium retention properties. EPHES US, a trial of a novel aldosterone antagonist, eplerenone, in patients with myocardial infarction, left ventricular dysfunction and pulmonary congesti on will determine whether this approach produces additive clinical benefits in modernly managed patients.